英科医疗
(300677)
| 流通市值：269.03亿 | | | 总市值：378.32亿 |
| 流通股本：4.66亿 | | | 总股本：6.55亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,887,034,413.31 | 9,925,819,444.72 | 7,424,714,825.22 | 4,913,439,043.41 |
| 营业收入 | 2,887,034,413.31 | 9,925,819,444.72 | 7,424,714,825.22 | 4,913,439,043.41 |
| 二、营业总成本 | 2,673,510,336.68 | 9,433,955,186.7 | 6,860,935,348.14 | 4,407,224,021.98 |
| 营业成本 | 2,119,986,845.14 | 7,531,555,720.01 | 5,665,117,617.56 | 3,722,998,252.37 |
| 税金及附加 | 25,698,425.67 | 97,295,051.67 | 68,628,887 | 51,146,652.78 |
| 销售费用 | 70,277,835.13 | 297,730,387.79 | 213,100,886.91 | 134,603,593.38 |
| 管理费用 | 160,922,156.79 | 686,464,281.55 | 477,842,557.57 | 292,139,371.7 |
| 研发费用 | 94,559,397.42 | 404,381,847.56 | 309,432,954.44 | 203,842,179.9 |
| 财务费用 | 202,065,676.53 | 416,527,898.12 | 126,812,444.66 | 2,493,971.85 |
| 其中:利息费用 | 96,384,248.61 | 369,151,102.52 | 304,854,695.34 | 190,204,566.97 |
| 其中:利息收入 | 48,595,312.13 | 367,932,996.49 | 328,946,772.41 | 237,250,957.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -257,350,762.92 | 318,499,359.53 | 245,295,913.05 | 228,448,036.21 |
| 加:投资收益 | 35,389,978.41 | 379,720,803.35 | 183,278,463.41 | 51,058,982.5 |
| 资产处置收益 | 56,324.99 | -397,114.67 | 273,845.85 | -11,052.2 |
| 资产减值损失(新) | 37,979,279.47 | -31,421,981.56 | 9,977,027.37 | -9,679,120.15 |
| 信用减值损失(新) | -453,085.38 | 6,306,257.36 | -1,944,683.07 | 220,801.19 |
| 其他收益 | 11,133,666.5 | 65,599,372.3 | 65,214,599.42 | 40,169,195.07 |
| 四、营业利润 | 40,279,477.7 | 1,230,170,954.33 | 1,065,874,643.11 | 816,421,864.05 |
| 加:营业外收入 | 6,716,984.52 | 22,878,771.51 | 1,802,882.51 | 1,210,380.04 |
| 减:营业外支出 | 648,479.45 | 23,309,581.23 | 7,186,025.48 | 5,591,742.45 |
| 五、利润总额 | 46,347,982.77 | 1,229,740,144.61 | 1,060,491,500.14 | 812,040,501.64 |
| 减:所得税费用 | 35,757,033.94 | 182,552,677.66 | 108,878,452.76 | 85,415,281.65 |
| 六、净利润 | 10,590,948.83 | 1,047,187,466.95 | 951,613,047.38 | 726,625,219.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 10,590,948.83 | 1,047,187,466.95 | 951,613,047.38 | 726,625,219.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 10,030,762.95 | 1,010,699,970.94 | 924,410,713.59 | 710,439,983.93 |
| 少数股东损益 | 560,185.88 | 36,487,496.01 | 27,202,333.79 | 16,185,236.06 |
| 扣除非经常损益后的净利润 | 181,971,193.45 | 396,851,301.89 | 484,481,437.92 | 400,201,229 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 1.58 | 1.45 | 1.12 |
| (二)稀释每股收益 | 0.02 | 1.57 | 1.45 | 1.12 |
| 八、其他综合收益 | -15,695,249.67 | -41,766,121.34 | -26,053,239.39 | -509,610.39 |
| 归属于母公司股东的其他综合收益 | -15,695,249.67 | -41,677,672.98 | -26,053,239.39 | -509,610.39 |
| 九、综合收益总额 | -5,104,300.84 | 1,005,421,345.61 | 925,559,807.99 | 726,115,609.6 |
| 归属于母公司股东的综合收益总额 | -5,664,486.72 | 969,022,297.96 | 898,357,474.2 | 709,930,373.54 |
| 归属于少数股东的综合收益总额 | 560,185.88 | 36,399,047.65 | 27,202,333.79 | 16,185,236.06 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-28 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |